UROLOGICAL CANCER: CHAARTED/GETUG 12—docetaxel in non-castrate prostate cancers

    loading  Checking for direct PDF access through Ovid

Abstract

Refers to Sweeney, C. J. et al. N. Engl. J. Med.373, 737–746 (2015) | Fizazi, K. et al. Lancet Oncol.16, 787–794 (2015)

In two recent phase III trials, investigators evaluated the addition of docetaxel to androgen-deprivation therapy for non-castrate prostate cancer. On the basis of the CHAARTED-trial findings, we can firmly conclude that this combination can be used in the metastatic setting. The results of the GETUG 12 trial are less informative, although some benefit for patients with high-risk localized prostate cancer was demonstrated.

Related Topics

    loading  Loading Related Articles